TrialSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.

Matteo Lambertini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.